Increased chemokine (C–C motif) ligand 21 expression and its correlation with osteopontin in Graves’ disease

Endocrine

Volumn 50, Issue 1, 2015, Pages 123-129

  Qi, Yicheng ^a   Li, Xiaoli ^a   Zhang, Qianwei ^a   Huang, Fengjiao ^a   Lin, Dongping ^b   Zhou, Yulin ^a   Hong, Jie ^a   Cui, Bin ^a   Wang, Weiqing ^a   Ning, Guang ^a   Wang, Shu ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

CCL21; Graves disease; Osteopontin; TRAb

Indexed keywords

OSTEOPONTIN; SECONDARY LYMPHOID TISSUE CHEMOKINE; THYROTROPIN RECEPTOR ANTIBODY; CCL21 PROTEIN, HUMAN; RECOMBINANT PROTEIN; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN-BINDING INHIBITORY IMMUNOGLOBULIN;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CD4+ T LYMPHOCYTE; CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE OVEREXPRESSION; GRAVES DISEASE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; QUANTITATIVE ANALYSIS; UPREGULATION; BLOOD; METABOLISM; MIDDLE AGED;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CHEMOKINE CCL21; FEMALE; GRAVES DISEASE; HUMANS; IMMUNOGLOBULINS, THYROID-STIMULATING; MALE; MIDDLE AGED; OSTEOPONTIN; RECOMBINANT PROTEINS;

EID: 84940439232     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-015-0552-7     Document Type: Article

References (34)

1. G.S. Cooper, B.C. Stroehla, The epidemiology of autoimmune diseases. Autoimmun. Rev. 2(3), 119–125 (2003)
2. D.S.A. McLeod, D.S. Cooper, The incidence and prevalence of thyroid autoimmunity. Endocrine 42, 252–265 (2012)
3. B. Rapoport, S.M. McLachlan, Thyroid autoimmunity. J. Clin. Invest. 108(9), 1253–1259 (2001)
4. P. Pozzilli, P. Carotenuto, G. Delitala, Lymphocytic traffic and homing into target tissue and the generation of endocrine autoimmunity. Clin. Endocrinol. 41(5), 545–554 (1994)
5. A.P. Weetman, Cellular immune responses in autoimmune thyroid disease. Clin. Endocrinol. 61(4), 405–413 (2004)
6. M. Rotondi, L. Chiovato, S. Romagnani, M. Serio, P. Romagnani, Role of chemokines in endocrine autoimmune diseases. Endocr. Rev. 28(5), 492–520 (2007)
7. R. Forster, A.C. Davalos-Misslitz, A. Rot, CCR7 and its ligands: balancing immunity and tolerance. Nat. Rev. Immunol. 8(5), 362–371 (2008)
8. O. Bjorkdahl, K.A. Barber, S.J. Brett, M.G. Daly, C. Plumpton, N.A. Elshourbagy, J.P. Tite, L.L. Thomsen, Characterization of CC-chemokine receptor 7 expression on murine T cells in lymphoid tissues. Immunology 110(2), 170–179 (2003)
9. M.D. Gunn, S. Kyuwa, C. Tam, T. Kakiuchi, A. Matsuzawa, L.T. Williams, H. Nakano, Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J. Exp. Med. 189(3), 451–460 (1999)
10. A.P. Martin, E.C. Coronel, G. Sano, S.C. Chen, G. Vassileva, C. Canasto-Chibuque, J.D. Sedgwick, P.S. Frenette, M. Lipp, G.C. Furtado, A novel model for lymphocytic infiltration of the thyroid gland generated by transgenic expression of the CC chemokine CCL21. J. Immunol. 173(8), 4791–4798 (2004)
11. T. Kuwabara, F. Ishikawa, T. Yasuda, K. Aritomi, H. Nakano, Y. Tanaka, Y. Okada, M. Lipp, T. Kakiuchi, CCR7 ligands are required for development of experimental autoimmune encephalomyelitis through generating IL-23-dependent Th17 cells. J. Immunol. 183(4), 2513–2521 (2009)
12. S.R. Pickens, N.D. Chamberlain, M.V. Volin, R.M. Pope, N.E. Talarico, A.M. Mandelin, S. Shahrara, Role of the CCL21 and CCR7 pathways in rheumatoid arthritis angiogenesis. Arthritis Rheum. 64(8), 2471–2481 (2012)
13. T. Watanabe, J. Suzuki, A. Mitsuo, S. Nakano, Y. Tamayama, A. Katagiri, H. Amano, S. Morimoto, Y. Tokano, Y. Takasaki, Striking alteration of some populations of T/B cells in systemic lupus erythematosus: relationship to expression of CD62L or some chemokine receptors. Lupus. 17(1), 26–33 (2008)
14. L.Y. Xu, X.R. Ma, Y.Y. Wang, X.L. Li, Y.C. Qi, B. Cui, X.Y. Li, G. Ning, S. Wang, The expression and pathophysiological role of osteopontin in Graves’ disease. J. Clin. Endocrinol. Metab. 96(11), E1866–E1870 (2011)
15. X.L. Li, Y.C. Qi, X.R. Ma, F.J. Huang, H. Guo, X.H. Jiang, J. Hong, D.P. Lin, B. Cui, G. Ning, S. Wang, Chemokine (C-C motif) ligand 20, a potential biomarker for Graves’ disease, is regulated by osteopontin. PloS ONE. 8(5), e64277 (2013)
16. Y.C. Qi, X.L. Li, X.R. Ma, L.Y. Xu, X.F. Zhang, X.H. Jiang, J. Hong, B. Cui, G. Ning, S. Wang, The role of osteopontin in the induction of the CD40 ligand in Graves’ disease. Clin. Endocrinol. 80(1), 128–134 (2014)
17. A.C. Renkl, J. Wussler, T. Ahrens, K. Thoma, S. Kon, T. Uede, S.F. Martin, J.C. Simon, J.M. Weiss, Osteopontin functionally activates dendritic cells and induces their differentiation toward a Th1-polarizing phenotype. Blood 106(3), 946–955 (2005)
18. G. Xu, H. Nie, N. Li, W. Zheng, D. Zhang, G. Feng, L. Ni, R. Xu, J. Hong, J.Z. Zhang, Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J. Clin. Invest. 115(4), 1060–1067 (2005)
19. G. Murugaiyan, A. Mittal, H.L. Weiner, Increased osteopontin expression in dendritic cells amplifies IL-17 production by CD4+ T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J. Immunol. 181(11), 7480–7488 (2008)
20. K.X. Wang, D.T. Denhardt, Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev. 19(5–6), 333–345 (2008)
21. M. Peiser, J. Koeck, C.J. Kirschning, B. Wittig, R. Wanner, Human Langerhans cells selectively activated via Toll-like receptor 2 agonists acquire migratory and CD4+ T cell stimulatory capacity. J. Leukoc. Biol. 83(5), 1118–1127 (2008)
22. L.Q. Xue, B. Han, C.M. Pan, H.D. Song, The association of SCGB3A2 polymorphisms with the risk of Graves’ disease: a meta-analysis. Endocrine 45, 365–369 (2014)
23. M. Rotondi, L. Chiovato, Vitamin D deficiency in patients with Graves’ disease: probably something more than a casual association. Endocrine 43, 3–5 (2013)
24. S.P. Commins, L. Borish, J.W. Steinke, Immunologic messenger molecules: cytokines, interferons, and chemokines. J. Allergy Clin. Immunol. 125(2 Suppl 2), S53–S72 (2010)
25. A. Antonelli, M. Rotondi, P. Fallahi, P. Romagnani, S.M. Ferrari, L. Barani, E. Ferrannini, M. Serio, Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves’ disease, and modulation by methimazole therapy. Clin. Endocrinol. 64(2), 189–195 (2006)
26. J. Domberg, C. Liu, C. Papewalis, C. Pfleger, K. Xu, H.S. Willenberg, D. Hermsen, W.A. Scherbaum, N.C. Schloot, M. Schott, Circulating chemokines in patients with autoimmune thyroid diseases. Horm. Metab. Res. 40(6), 416–421 (2008)
27. A. Antonelli, S.M. Ferrari, D. Giuggioli, E. Ferrannini, C. Ferri, P. Fallahi, Chemokine (C–X–C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun. Rev. 13, 272–280 (2014)
28. S. Costagliola, N.G. Morgenthaler, R. Hoermann, K. Badenhoop, J. Struck, D. Freitag, S. Poertl, W. Weglohner, J.M. Hollidt, B. Quadbeck, Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves’ disease. J. Clin. Endocrinol. Metab. 84(1), 90–97 (1999)
29. C. Cappelli, E. Gandossi, M. Castellano, C. Pizzocaro, B. Agosti, A. Delbarba, I. Pirola, E. De Martino, E.A. Rosei, Prognostic value of thyrotropin receptor antibodies (TRAb) in Graves’ disease: a 120 months prospective study. Endocr. J. 54(5), 713–720 (2007)
30. F. Menconi, C. Marcocci, M. Marino, Diagnosis and classification of Graves’ disease. Autoimmun. Rev. 13(4–5), 398–402 (2014)
31. N. Takasu, N.J. Yoshimura, Hashimoto’s thyroiditis: TGAb, TPOAb, TRAb and recovery from hypothyroidism. Expert Rev. Clin. Immunol. 4(2), 221–237 (2008)
32. K. Schneider, K.G. Potter, C.F. Ware, Lymphotoxin and LIGHT signaling pathways and target genes. Immunol. Rev. 202, 49–66 (2004)
33. S.R. Pickens, N.D. Chamberlain, M.V. Volin, R.M. Pope, A.M. Mandelin, S. Shahrara, Characterization of CCL19 and CCL21 in rheumatoid arthritis. Arthritis Rheum. 63(4), 914–922 (2011)
34. G.F. Weber, S. Ashkar, M.J. Glimcher, H. Cantor, Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science. 271(5248), 509–512 (1996)